.navbar .collapse { display: block; } .mobile-nav { max-height: none !important; } @media screen and (min-width: 1200px) { .navbar #basic-navbar-nav .navbar-nav { position: static !important; } }

Spotlight

COVID-19
Sickle Cell Disease
Strains of C. Difficile

ClinicalSee All >

ADHD
Allergy
Arterial Disease
Cardiology
Dermatology
Diabetes
Gastroenterology
Geriatric Medicine
Infectious Disease
Inflammation
Neurology
Psychiatry
Pulmonology
Rheumatology

Video Series

Insights
News Network
Peers & Perspectives
Post Conference Perspectives

About Us
Advertise
Editorial
Contact Us
Do Not Sell My Information
Privacy
Terms & Conditions

Treating Advanced RAI-Refractory DTC: A Two-Way Street: Medical Oncology and Endocrinology

EP. 1: Differentiated Thyroid Cancer: Increasing Incidence

January 29th 2021

EP. 2: DTC: Histological Subtypes and Tumor Differentiation

January 29th 2021

EP. 3: Role of Radioiodine Treatment in DTC

January 29th 2021

EP. 4: Thyrotropin Suppression as DTC Treatment Option

January 29th 2021

EP. 5: Clinical Scenarios to Consider for RAI-Refractory DTC

January 29th 2021

EP. 6: Discussing Iodine-Refractory DTC With Patients

January 29th 2021

EP. 7: Management of DTC in Clinical Practice

February 4th 2021

EP. 8: Roles and Communication in Treatment in DTC

February 4th 2021

EP. 9: Understanding Sequencing and What to Look for in DTC

February 11th 2021

EP. 10: Approaching Treatment of Low-Volume DTC

February 11th 2021